Revision as of 07:28, 9 May 2024 edit Boghog (talk \| contribs) Autopatrolled, Extended confirmed users, IP block exemptions, New page reviewers, Pending changes reviewers, Rollbackers, Template editors 137,265 edits consistent citation formatting ← Previous edit		Revision as of 07:14, 11 May 2024 edit undo Yun4173 (talk \| contribs) 1 edit m →Medical uses Tag: Visual edit Next edit →
Line 137: It appears to be as effective as [[warfarin]] in preventing non-hemorrhagic strokes and embolic events in those with atrial fibrillation not due to valve problems.<ref>{{cite journal \| vauthors = Gómez-Outes A, Terleira-Fernández AI, Calvo-Rojas G, Suárez-Gea ML, Vargas-Castrillón E \| title = Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups \| journal = Thrombosis \| volume = 2013 \| pages = 640723 \| date = 2013 \| pmid = 24455237 \| pmc = 3885278 \| doi = 10.1155/2013/640723 \| doi-access = free }}</ref><ref>{{cite journal \| vauthors = Lowenstern A, Al-Khatib SM, Sharan L, Chatterjee R, Allen LaPointe NM, Shah B, Borre ED, Raitz G, Goode A, Yapa R, Davis JK, Lallinger K, Schmidt R, Kosinski AS, Sanders GD \| title = Interventions for Preventing Thromboembolic Events in Patients With Atrial Fibrillation: A Systematic Review \| journal = Annals of Internal Medicine \| volume = 169 \| issue = 11 \| pages = 774–787 \| date = December 2018 \| pmid = 30383133 \| pmc = 6825839 \| doi = 10.7326/M18-1523 }}</ref><ref>{{cite report \| vauthors = Sanders GD, Lowenstern A, Borre E, Chatterjee R, Goode A, Sharan L, LaPointe NM, Raitz G, Shah B, Yapa R, Davis JK, Lallinger K, Schmidt R, Kosinski A, Al-Khatib S \| title = Stroke Prevention in Patients With Atrial Fibrillation: A Systematic Review Update \| location = Rockville (MD) \| work = Agency for Healthcare Research and Quality (US) \| date = October 2018 \| id = Report No.: 18-EHC018-EFReport No.: 2018-SR-04. \| url = https://effectivehealthcare.ahrq.gov/topics/stroke-afib-update/research-2018 \| doi = 10.23970/ahrqepccer214 \| pmid = 30480925 \| access-date = 31 May 2023 \| archive-date = 29 March 2019 \| archive-url = https://web.archive.org/web/20190329195137/https://effectivehealthcare.ahrq.gov/topics/stroke-afib-update/research-2018 \| url-status = live \| doi-access = free }}</ref> In 2022, aan ~~comparative~~observational metal-analysis study was performed on direct oral anticoagulants for patients with atrial fibrillation. ~~Results~~The ~~demonstrated~~study ~~[[apixaban]]~~found ~~use~~that ~~was~~dabigatran ~~associated~~had ~~with lower risk for gastrointestinal bleeding and similar~~comparable rates of ischemic stroke or systemic embolism, intracerebral ~~brain hemorrhage~~haemorrhage, and all-cause mortality when compared ~~with~~to ~~dabigatran~~other anticoagulants like apixaban, [[edoxaban]], and [[rivaroxaban]]. Notably, apixaban was associated with a lower risk of gastrointestinal bleeding than dabigatran and the others. This finding was generally steady for patients aged 80 years or older and those with chronic kidney disease.<ref>{{cite journal \| vauthors = Lau WC, Torre CO, Man KK, Stewart HM, Seager S, Van Zandt M, Reich C, Li J, Brewster J, Lip GY, Hingorani AD, Wei L, Wong IC \| title = Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation : A Multinational Population-Based Cohort Study \| journal = Annals of Internal Medicine \| volume = 175 \| issue = 11 \| pages = 1515–1524 \| date = November 2022 \| pmid = 36315950 \| doi = 10.7326/M22-0511 \| s2cid = 253238819 }}</ref> ==Contraindications==

Dabigatran: Difference between revisions